Revolution Historical Financial Ratios
RVMDW Stock | 0.09 0 4.88% |
Revolution Medicines, is promptly reporting on over 80 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 14.18, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 5.04 will help investors to properly organize and evaluate Revolution Medicines, financial condition quickly.
Revolution |
About Revolution Financial Ratios Analysis
Revolution Medicines,Financial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Revolution Medicines, investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Revolution financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Revolution Medicines, history.
Revolution Medicines, Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Revolution Medicines, stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Revolution Medicines, sales, a figure that is much harder to manipulate than other Revolution Medicines, Warrant multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from Revolution Medicines,'s fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Revolution Medicines, current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines, Warrant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. At this time, Revolution Medicines,'s Cash Per Share is fairly stable compared to the past year. Tangible Book Value Per Share is likely to climb to 13.73 in 2025, whereas Free Cash Flow Yield is likely to drop (0.08) in 2025.
2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 48.21 | 39.53 | 45.45 | 75.46 | PTB Ratio | 2.8 | 1.78 | 3.24 | 3.08 |
Revolution Medicines, fundamentals Correlations
Click cells to compare fundamentals
Revolution Medicines, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Revolution Medicines, fundamentals Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Price To Sales Ratio | 61.34 | 62.35 | 54.28 | 280.24 | 252.21 | 264.82 | |
Ptb Ratio | 5.55 | 3.04 | 2.8 | 1.78 | 3.24 | 3.08 | |
Days Sales Outstanding | 54.29 | 73.63 | 48.21 | 39.53 | 45.45 | 75.46 | |
Book Value Per Share | 7.13 | 8.28 | 8.5 | 16.14 | 13.5 | 14.18 | |
Free Cash Flow Yield | (0.0391) | (0.0839) | (0.12) | (0.11) | (0.0774) | (0.0813) | |
Operating Cash Flow Per Share | (1.5) | (2.02) | (2.78) | (3.1) | (3.32) | (3.49) | |
Stock Based Compensation To Revenue | 0.21 | 0.71 | 0.88 | 5.33 | 4.8 | 5.04 | |
Capex To Depreciation | 0.45 | 0.89 | 1.12 | 0.83 | (0.24) | (0.23) | |
Pb Ratio | 5.55 | 3.04 | 2.8 | 1.78 | 3.24 | 3.08 | |
Ev To Sales | 59.68 | 60.93 | 51.54 | 227.71 | 204.94 | 215.19 | |
Free Cash Flow Per Share | (1.55) | (2.11) | (2.92) | (3.17) | (3.38) | (3.55) | |
Net Income Per Share | (1.62) | (2.47) | (3.08) | (3.86) | (3.58) | (3.76) | |
Payables Turnover | 8.05 | 10.49 | 0.52 | 0.45 | 0.41 | 0.39 | |
Sales General And Administrative To Revenue | 0.5 | 1.04 | 1.15 | 6.53 | 5.88 | 6.17 | |
Research And Ddevelopement To Revenue | 3.08 | 6.36 | 7.15 | 36.54 | 32.89 | 34.53 | |
Capex To Revenue | 0.0682 | 0.22 | 0.31 | 0.67 | 0.6 | 0.63 | |
Cash Per Share | 6.62 | 7.93 | 8.0 | 16.38 | 13.65 | 14.33 | |
Pocfratio | (26.35) | (12.45) | (8.56) | (9.26) | (13.16) | (12.5) | |
Interest Coverage | (510.57) | (1.6K) | (15.7K) | (1.6K) | (1.8K) | (1.9K) | |
Capex To Operating Cash Flow | (0.0293) | (0.0444) | (0.0482) | (0.022) | (0.0185) | (0.0176) | |
Pfcf Ratio | (25.6) | (11.92) | (8.16) | (9.06) | (12.92) | (13.57) | |
Days Payables Outstanding | 45.35 | 34.8 | 699.78 | 805.37 | 926.18 | 678.13 | |
Income Quality | 1.04 | 0.93 | 0.79 | 0.9 | 0.8 | 0.62 | |
Roe | (0.23) | (0.3) | (0.36) | (0.24) | (0.26) | (0.28) | |
Ev To Operating Cash Flow | (25.63) | (12.17) | (8.13) | (7.52) | (12.43) | (11.81) | |
Pe Ratio | (24.38) | (10.19) | (7.72) | (7.44) | (12.23) | (12.84) | |
Return On Tangible Assets | (0.33) | (0.22) | (0.27) | (0.34) | (0.24) | (0.25) | |
Ev To Free Cash Flow | (24.9) | (11.65) | (7.75) | (7.36) | (12.21) | (12.82) | |
Earnings Yield | (0.028) | (0.041) | (0.0981) | (0.13) | (0.0818) | (0.0859) | |
Intangibles To Total Assets | 0.13 | 0.1 | 0.0904 | 0.0351 | 0.0279 | 0.0265 | |
Net Debt To E B I T D A | 0.7 | 0.23 | 0.41 | 1.41 | 0.59 | 0.58 | |
Current Ratio | 9.63 | 30.48 | 10.65 | 13.06 | 14.2 | 8.52 | |
Tangible Book Value Per Share | 5.99 | 7.25 | 7.59 | 15.5 | 13.08 | 13.73 | |
Receivables Turnover | 6.72 | 4.96 | 7.57 | 9.23 | 8.31 | 4.93 | |
Graham Number | 16.14 | 21.44 | 24.29 | 37.42 | 32.97 | 34.62 | |
Shareholders Equity Per Share | 7.13 | 8.28 | 8.5 | 16.14 | 13.5 | 14.18 | |
Debt To Equity | 0.0688 | 0.11 | 0.0937 | 0.0482 | 0.06 | 0.0438 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Revolution Stock Analysis
When running Revolution Medicines,'s price analysis, check to measure Revolution Medicines,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines, is operating at the current time. Most of Revolution Medicines,'s value examination focuses on studying past and present price action to predict the probability of Revolution Medicines,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines,'s price. Additionally, you may evaluate how the addition of Revolution Medicines, to your portfolios can decrease your overall portfolio volatility.